NASDAQ:ETON - Nasdaq - US29772L1089 - Common Stock - Currency: USD
ETON PHARMACEUTICALS INC
NASDAQ:ETON (1/31/2025, 8:29:02 PM)
After market: 17.5 -0.18 (-1.02%)17.68
+0.36 (+2.08%)
The current stock price of ETON is 17.68 USD. In the past month the price increased by 32.73%. In the past year, price increased by 293.76%.
Adds an additional commercial and strategic rare disease product to Eton’s portfolioGalzin is FDA-approved for the treatment of the ultra-rare metabolic...
Acquisition bolsters Eton’s commercial pediatric endocrinology portfolioProduct is now available through AnovoRx, a specialty pharmacy dedicated to serving...
Clinical Trial Demonstrates Clinical and Statistical Improvement in Metabolic Control During Prolonged Fasting in PKU Patients - Results Expected to Promote Awareness and Adoption of PKU GOLIKE®
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 79.75 | 769.97B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 28.43 | 374.97B | ||
JNJ | JOHNSON & JOHNSON | 15.23 | 366.32B | ||
MRK | MERCK & CO. INC. | 16.61 | 249.98B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 18.57 | 219.43B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 14.04 | 209.36B | ||
PFE | PFIZER INC | 10.28 | 150.29B | ||
SNY | SANOFI-ADR | 14.85 | 136.24B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 50.38 | 119.56B | ||
ZTS | ZOETIS INC | 29.67 | 77.10B | ||
GSK | GSK PLC-SPON ADR | 8.5 | 71.96B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 22.32 | 42.45B |
Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. The company is headquartered in Deer Park, Illinois and currently employs 30 full-time employees. The company went IPO on 2018-11-09. The firm is focused on developing and commercializing treatments for rare diseases. The firm has five commercial rare disease products: ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The firm has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector. ALKINDI SPRINKLE is a granule hydrocortisone formulation designed to help provide accurate dosing for newborns and children with adrenal insufficiency. PKU GOLIKE is a next generation medical formula product engineered with the patent protected, pharmaceutical grade Physiomimic technology for the dietary management of phenylketonuria (PKU) under medical supervision. Carglumic Acid is used for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is developed for the treatment of homocystinuria.
ETON PHARMACEUTICALS INC
21925 W Field Pkwy Ste 235
Deer Park ILLINOIS 60010 US
CEO: Sean E. Brynjelsen
Employees: 30
Company Website: https://etonpharma.com/
Investor Relations: http://ir.etonpharma.com
Phone: 18477877361
The current stock price of ETON is 17.68 USD.
The exchange symbol of ETON PHARMACEUTICALS INC is ETON and it is listed on the Nasdaq exchange.
ETON stock is listed on the Nasdaq exchange.
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for ETON, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of ETON.
ETON does not pay a dividend.
ETON does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.21).
The outstanding short interest for ETON is 0.97% of its float.
ChartMill assigns a technical rating of 10 / 10 to ETON. When comparing the yearly performance of all stocks, ETON is one of the better performing stocks in the market, outperforming 98.64% of all stocks.
ChartMill assigns a fundamental rating of 4 / 10 to ETON. While ETON seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months ETON reported a non-GAAP Earnings per Share(EPS) of -0.21. The EPS increased by -400% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -15.29% | ||
ROE | -34.3% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 83% to ETON. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of -129.5% and a revenue growth 18.53% for ETON